Federally-Listed PSOs

Below is a list of PSOs that are currently listed by AHRQ. A health care provider can only obtain the confidentiality and privilege protections of the Patient Safety Act by working with a Federally-listed PSO.

Use the categories on the left to filter the list of PSOs or search a PSO name.

Note: AHRQ updates the PSO information contained within the directories weekly, as needed; changes are made when there are newly listed PSOs and/or when existing information requires revision. Changes that would otherwise be effective on a weekend day or holiday will be effective on the next business day. Information contained in the directories is based on attestations that the PSOs provide. To update PSO contact information, please use the Change of Listing Information form; to update profile information, please go to the PSO PPC Web site.

There are 94 total PSOs listed by AHRQ.

PLEASE NOTE: To search for a PSO by State, use the 2 letter state abbreviation. Example: Kansas = KS

Alliance for Patient Medication Safety - P0020
Component of Parent Org(s):
  • National Alliance of State Pharmacy Associations (NASPA)
Effective Date and Time of Initial Listing: December 10, 2008 12:01 AM ET
PSO Mailing Address: 2530 Professional Road, Suite 200, Richmond, VA 23235
PSO Phone Number: 804-422-6311
Point of Contact: Taramarie (Tara) Modisett
Point of Contact Phone: 804-422-6311, ext. 107
Point of Contact Email: tara@naspa.us (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 12/10/2020 through 12/09/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
Enterprise Patient Safety Organization, L.L.C - P0155
Component of Parent Org(s):
  • CVS Pharmacy, Inc.
Effective Date and Time of Initial Listing: April 22, 2014 12:01 AM ET
PSO Mailing Address: One CVS Drive, MC 2345, Woonsocket, RI 02895
PSO Phone Number: 401-770-5215
Point of Contact: Ann Louise Puopolo
Point of Contact Phone: 401-770-5215
Point of Contact Email: annlouise.puopolo@cvshealth.com (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 04/22/2020 through 04/21/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: Yes
HPI Press Ganey PSO - P0185
Component of Parent Org(s):
  • Press Ganey
Effective Date and Time of Initial Listing: December 12, 2016 12:01 AM ET
PSO Mailing Address: 5041 Corporate Woods Drive Ste 180, Virginia Beach, VA 23462
PSO Phone Number: 913-800-4954
Point of Contact: Caryn Lea Woods
Point of Contact Phone: 757-226-7479
Point of Contact Email: Caryn.Woods@pressganey.com (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 12/12/2020 through 12/11/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
Somnia Patient Safety Organization, Inc. - P0112
Component of Parent Org(s):
  • Somnia, Inc.
Effective Date and Time of Initial Listing: July 20, 2011 12:01 AM ET
PSO Mailing Address: 450 Mamaroneck Ave., Suite 201, Harrison, NY 10528
PSO Phone Number: 914-336-1840
Point of Contact: Stephen Songhurst
Point of Contact Phone: 914-500-9105
Point of Contact Email: Ssonghurst@somniainc.com (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 07/20/2019 through 07/19/2021
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
USAP PSO - P0178
Component of Parent Org(s):
  • US Anesthesia Partners
Effective Date and Time of Initial Listing: June 15, 2016 12:01 AM ET
PSO Mailing Address: 12222 Merit Drive, Suite 700, Dallas, TX 75251
PSO Phone Number: 972-663-8522
Point of Contact: Ann McFarland Limbach RN, JD, CPHRM
Point of Contact Phone: 205-678-8342
Point of Contact Email: ann.limbach@usap.com (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 06/15/2020 through 06/14/2022
Disclosures & Finding: The Department of Health and Human Services determined no action was required regarding the PSO's relationships with the following contracting provider(s):
  • US Anesthesia Providers of Florida
Subject to FDA-Regulated Reporting Entity Guidance: No